releasing hormone agonist therapy

DRUG7 trials

Sponsors

Radiation Therapy Oncology Group, Peter MacCallum Cancer Centre, Australia, OHSU Knight Cancer Institute, Azienda Ospedaliero-Universitaria di Modena, A.O.U. San Giovanni Battista di Torino, Italy

Conditions

Breast CancerPainProstate Cancer

Phase 2

Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer

WithdrawnNCT00244920

OHSU Knight Cancer InstituteProstate Cancer

Start: 2002-01-31End: 2007-06-30Updated: 2012-05-28

Phase 3

Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

CompletedNCT00023829

Radiation Therapy Oncology GroupProstate Cancer

Start: 2001-08-31End: 2004-06-30Updated: 2020-10-22

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

CompletedNCT00030654

Radiation Therapy Oncology GroupProstate Cancer

Start: 2002-10-31End: 2005-02-04Updated: 2020-10-22

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

Peter MacCallum Cancer Centre, AustraliaProstate Cancer

Start: 2004-10-31Target: 2000Updated: 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Azienda Ospedaliero-Universitaria di ModenaBreast Cancer

Start: 2007-12-31Target: 2500Updated: 2013-08-07

Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer

A.O.U. San Giovanni Battista di Torino, ItalyPain, Prostate Cancer

Start: 2005-04-30Target: 200Updated: 2013-08-12

Unknown Phase

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

Cancer Research UKProstate Cancer

Start: 2008-09-30Target: 120Updated: 2014-01-10

Related Papers

Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast Cancer

JAMA Oncology2025-02-139 citations

Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.

Journal of Clinical Oncology2023-06-077 citations

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.

2023-02-048 citations

Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.

Journal of Clinical Oncology2022-06-012 citations

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.

2019-11-215 citations

PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.

Journal of Clinical Oncology2019-05-208 citations

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.

2018-12-01110 citations

Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.

Journal of Clinical Oncology2018-05-2011 citations

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

2017-07-2843 citations

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.

Journal of Clinical Oncology2017-05-2036 citations

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

2016-05-04160 citations